1. 42 USC §262. Regulation of biological products (2010). http://uscode.house.gov/view.xhtml?req=(title:42%20section:262%20edition:prelim)#sourcecredit . Accessed 1 Oct 2017.
2. Berger RL, Hsu JC. Bioequivalence trials, intersection-union tests and equivalence confidence sets. Stat. Sci. 1996;11:283–319.
3. Blackwell S, Crawford J. Filgrastim (r-methug-csf) in the chemotherapy setting. In: Morstyn G, Dexter TM, editors. Filgrastim (r-metHuG-CSF) in clinical practice. New York: Marcel Dekker; 1994. pp. 103–116.
4. Christl LA, Woodcock J, Kozlowski S. Biosimilars: the us regulatory framework. Annu. Rev. Med. 2017;68:243–254.
5. Code of Federal Regulations. 21cfr314.92, current as of April 1 2017. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=314 ; 2017a. Accessed 29 Dec 2017.